Deals Report: Bispecific space continues to foster partnerships
Plus: Otsuka in $800M takeout of Jnana, BioNTech dropping Genmab’s acasunlimab
The latest biopharma partnerships include at least three licensing deals in the hot bispecific space in the past week, even as a collaboration between BioNTech and Genmab for one such late-stage asset fizzled.
Last week saw one notable M&A announcement — Otsuka Holdings Co. Ltd. (Tokyo:4578) acquired Jnana Therapeutics Inc. for $800 million. The takeout, which includes $325 million in potential development and regulatory milestones, gives Otsuka a small molecule SLC6A19 inhibitor to treat phenylketonuria. ...
BCIQ Company Profiles
BCIQ Target Profiles
Cytotoxic T-lymphocyte associated protein 4 (CTLA-4) (CTLA4) (CD152)
Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu)
Programmed cell death 1 ligand 1 (PD-L1) (B7-H1) (CD274)
Prostate-specific membrane antigen (PSMA) (FOLH1) (GCPII)
Tumor necrosis factor (TNF) receptor superfamily member 9 (4-1BB) (TNFRSF9) (CD137)